Uroplasty Inc (UPI, Financial) filed Quarterly Report for the period ended 2012-12-31.
Uroplasty, Inc. has a market cap of $55.4 million; its shares were traded at around $2.64 with and P/S ratio of 2.4.
Net sales to customers in the U.S. of $4.1 million during the three months ended December 31, 2012, represented an increase of $528,000, or 15%, over Net sales of $3.6 million for the three months ended December 31, 2011. Net sales to customers in the U.S. of $12.4 million during the nine months ended December 31, 2012, represented an increase of $2.5 million, or 25%, over Net sales of $9.9 million for the nine months ended December 31, 2011.
Net sales to customers outside the U.S. for the three months ended December 31, 2012 decreased 16% to $1.5 million compared to $1.8 million for the three months ended December 31, 2011. Excluding the translation impact of fluctuations in foreign currency exchange rates, Net sales decreased by approximately 14%. Net sales to customers outside the U.S. for the nine months ended December 31, 2012 were $4.5 million compared to $5.1 million for the nine months ended December 31, 2011, a decrease of 11%. Excluding the translation impact of fluctuations in foreign currency exchange rates, Net sales decreased by approximately 5%. Macroplastique sales declined 24% to $672,000 in the third fiscal quarter and declined 23% to $2.1 million for the nine months ended December 31, 2012 over the corresponding year ago periods. The decline of the Macroplastique sales is primarily caused by the irregular ordering pattern of one of our main distributors.
Urgent PC sales to customers outside of the U.S. of $556,000 for the three months ended December 31, 2012 decreased 4% from $581,000 for the same period last year. The decrease in sales is mainly attributed to price reduction in one geographic area due to reimbursement challenges as well as to local competition. In addition the last year quarter contained a one-time order for a third party funded clinical study. Urgent PC sales of $1.6 million for the nine months ended December 31, 2012 increased 15% from $1.4 million for the same period last year. Excluding the translation impact of fluctuations in foreign currency exchange rates, Urgent PC sales increased by approximately 21%. The increase in sales is attributed to the increase in adoption of the product by our customers, primarily in the United Kingdom.
Selling and Marketing Expenses (S&M): S&M expenses of $3.7 million during the three months ended December 31, 2012 decreased $177,000, from $3.9 million, during the same period in 2011. S&M expenses during the three months ended December 31, 2012, decreased primarily because of a $207,000 decrease in compensation-related costs, offset by a $50,000 increase in travel costs. S&M expenses of $11.4 million during the nine months ended December 31, 2012 increased $57,000 compared to the same period last year. S&M expenses during the nine months ended December 31, 2012, increased primarily because of a $255,000 increase in travel costs and a $62,000 increase in marketing related costs to support the increase in personnel in our U.S field sales and support organization, offset by a $317,000 decrease in compensation related costs as a result of reducing our bonus and incentive related costs by $404,000.
Read the The complete Report
Uroplasty, Inc. has a market cap of $55.4 million; its shares were traded at around $2.64 with and P/S ratio of 2.4.
Highlight of Business Operations:
Net Sales: During the three months ended December 31, 2012, consolidated Net sales of $5.6 million represented a $246,000, or a 5% increase, over Net sales of $5.3 million for the three months ended December 31, 2011. During the nine months ended December 31, 2012, consolidated Net sales of $16.9 million represented a $1.9 million, or a 13%, increase over net sales of $15.0 million for the nine months ended December 31, 2011.Net sales to customers in the U.S. of $4.1 million during the three months ended December 31, 2012, represented an increase of $528,000, or 15%, over Net sales of $3.6 million for the three months ended December 31, 2011. Net sales to customers in the U.S. of $12.4 million during the nine months ended December 31, 2012, represented an increase of $2.5 million, or 25%, over Net sales of $9.9 million for the nine months ended December 31, 2011.
Net sales to customers outside the U.S. for the three months ended December 31, 2012 decreased 16% to $1.5 million compared to $1.8 million for the three months ended December 31, 2011. Excluding the translation impact of fluctuations in foreign currency exchange rates, Net sales decreased by approximately 14%. Net sales to customers outside the U.S. for the nine months ended December 31, 2012 were $4.5 million compared to $5.1 million for the nine months ended December 31, 2011, a decrease of 11%. Excluding the translation impact of fluctuations in foreign currency exchange rates, Net sales decreased by approximately 5%. Macroplastique sales declined 24% to $672,000 in the third fiscal quarter and declined 23% to $2.1 million for the nine months ended December 31, 2012 over the corresponding year ago periods. The decline of the Macroplastique sales is primarily caused by the irregular ordering pattern of one of our main distributors.
Urgent PC sales to customers outside of the U.S. of $556,000 for the three months ended December 31, 2012 decreased 4% from $581,000 for the same period last year. The decrease in sales is mainly attributed to price reduction in one geographic area due to reimbursement challenges as well as to local competition. In addition the last year quarter contained a one-time order for a third party funded clinical study. Urgent PC sales of $1.6 million for the nine months ended December 31, 2012 increased 15% from $1.4 million for the same period last year. Excluding the translation impact of fluctuations in foreign currency exchange rates, Urgent PC sales increased by approximately 21%. The increase in sales is attributed to the increase in adoption of the product by our customers, primarily in the United Kingdom.
Selling and Marketing Expenses (S&M): S&M expenses of $3.7 million during the three months ended December 31, 2012 decreased $177,000, from $3.9 million, during the same period in 2011. S&M expenses during the three months ended December 31, 2012, decreased primarily because of a $207,000 decrease in compensation-related costs, offset by a $50,000 increase in travel costs. S&M expenses of $11.4 million during the nine months ended December 31, 2012 increased $57,000 compared to the same period last year. S&M expenses during the nine months ended December 31, 2012, increased primarily because of a $255,000 increase in travel costs and a $62,000 increase in marketing related costs to support the increase in personnel in our U.S field sales and support organization, offset by a $317,000 decrease in compensation related costs as a result of reducing our bonus and incentive related costs by $404,000.
Read the The complete Report
